Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144487 | 0.81 | ALDH1A1 (0.46) | SMN1; SMN2TP53MAPTSTK17BNPC1 | |
| SCHEMBL19328487 | 0.81 | PDCD1 (0.40) | SMN1; SMN2TP53MAPTSTK17BNPC1 | |
| SCHEMBL30682021 | 0.79 | MAP4K4 (0.41) | SMN1; SMN2TP53MAPTEPHX2STK17B | |
| SCHEMBL22130301 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2TP53MAPTNPC1RAB9A | |
| Cyclopropane SCHEMBL2438672 | 0.78 | TP53 (0.49) | SMN1; SMN2TP53MAPTSTK17BNPC1 | |
| Cyclopropane SCHEMBL2444392 | 0.78 | STK17B (0.44) | SMN1; SMN2TP53MAPTEPHX2STK17B | |
| SCHEMBL7089986 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2TP53MAPTEPHX2NPC1 | |
| SCHEMBL7247038 | 0.77 | HIF1A (0.47) | NPC1RAB9AHIF1ALMNAALDH1A1 | |
| SCHEMBL30123788 | 0.76 | MEN1 (0.49) | SMN1; SMN2TP53MAPTNPC1RAB9A | |
| SCHEMBL22130267 | 0.76 | TP53 (0.70) | SMN1; SMN2TP53MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-9796742-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-9783556-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-10 | — | — | US | disclosed |
| EP-2890701-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-03-29 | — | — | EP | disclosed |
| EP-2890460-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20160340375-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20150225427-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2890460-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890701-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014033446-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033449-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340375-A1 | KINASE INHIBITORS | SYK, LYN, BTK | SMN1; SMN2 4324/4885TP53 2631/4885MAPT 4124/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | SMN1; SMN2 2517/4885TP53 4848/4885MAPT 4824/4885 |
| US-20150225427-A1 | KINASE INHIBITORS | SYK, LYN, BTK | SMN1; SMN2 4361/4885TP53 2257/4885MAPT 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.